<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02397720</url>
  </required_header>
  <id_info>
    <org_study_id>2014-0861</org_study_id>
    <secondary_id>NCI-2015-00593</secondary_id>
    <nct_id>NCT02397720</nct_id>
  </id_info>
  <brief_title>An Open-Label Phase II Study of Nivolumab (BMS-936558) in Combination With 5-azacytidine (Vidaza) or Nivolumab With Ipilimumab in Combination With 5-azacytidine for the Treatment of Patients With Refractory/ Relapsed Acute Myeloid Leukemia and Newly Diagnosed Older AML (&gt;65 Years) Patients</brief_title>
  <official_title>An Open-Label Phase II Study of Nivolumab (BMS-936558) in Combination With 5-azacytidine (Vidaza) or Nivolumab With Ipilimumab in Combination With 5-azacytidine for the Treatment of Patients With Refractory/ Relapsed Acute Myeloid Leukemia and Newly Diagnosed Older AML (&gt;65 Years) Patients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>M.D. Anderson Cancer Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Bristol-Myers Squibb</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>M.D. Anderson Cancer Center</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      There are 2 Arms in this study each with 2 parts. If you are eligible, you will be assigned
      to an Arm and a part when you join the study.

      Arm 1: There are 2 parts : Part A (dose escalation) and Part B (dose expansion).

      The goal of Part A of this clinical research study is to find the highest tolerable dose of
      nivolumab and azacitidine that can be given to patients with AML. The goal of Part B of this
      study is to learn if the dose found in Part A can help to control AML.

      The safety of this drug combination will also be studied.

      Arm 2: There are 2 parts: Part A (dose escalation) and Part B (dose expansion).

      The goal of Part A of this clinical research study is to find the highest tolerable dose of
      nivolumab, azacitidine, and ipilimumab that can be given to patients with AML. The goal of
      Part B of this study is to learn if the dose found in Part A can help to control AML.

      The safety of this drug combination will also be studied.

      This is an investigational study. Azacitidine is FDA approved and commercially available for
      the treatment of myelodysplastic syndrome (MDS) and it is approved as frontline therapy for
      AML in elderly participants. Nivolumab is commercially available and approved for the
      treatment of certain types of melanoma and lung cancers. Their use in this study is
      considered investigational. The study doctor can explain how the study drugs are designed to
      work.

      Up to 182 participants will take part in this study. All will be enrolled at MD Anderson.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Study Groups:

      If you are found to be eligible to take part in this study, you will be assigned to a study
      group based on when you join this study.

      Arm 1:

      Up to 5 groups of up to 6 participants will be enrolled in Part A of the study, and up to 110
      participants will be enrolled in Part B of the study.

      If you are enrolled in Part A of the study, the dose of nivolumab and azacitidine you receive
      will depend on when you joined this study. The first group of participants will receive the
      starting dose levels of nivolumab and azacitidine. If intolerable side effects are seen, the
      next group may receive a lower dose level of nivolumab and/or azacitidine. This will continue
      until the highest tolerable combination dose is found.

      If you are enrolled in Part B, you will receive nivolumab and azacitidine at the highest dose
      that was tolerated in Part A. There are 2 groups in Part B: Part 1B and Part 2B. Up to 70
      participants with AML who are younger than 65 years old will be enrolled in Part 1B and up to
      40 participants with AML who are 65 years or older will be enrolled in Part 2B.

      Arm 2:

      Up to 4 groups of up to 6 participants will be enrolled in Part A of the study, and up to 60
      participants will be enrolled in Part B of the study.

      If you are enrolled in Part A of the study, the dose of nivolumab, azacitidine, and
      ipilimumab you receive will depend on when you joined this study. The first group of
      participants will receive the starting dose levels of nivolumab, azacitidine and ipilimumab.
      If intolerable side effects are seen, the next group may receive a lower dose level of
      nivolumab, azacitidine and/or ipilimumab. This will continue until the highest tolerable
      combination dose is found.

      If you are enrolled in Part B, you will receive nivolumab, azacitidine, and ipilimumab at the
      highest dose that was tolerated in Part A. There are 2 groups in Part B: Part 1B and Part 2B.
      Up to 30 participants with AML who are younger than 65 years old will be enrolled in Part 1B
      and up to 30 participants with AML who are 65 years or older will be enrolled in Part 2B.

      Study Treatment:

      Each cycle will be about 28 days long. However, cycles may be longer or shorter depending on
      how the disease responds to the treatment and what the doctor thinks is in your best
      interest. The study doctor will tell you if your study cycles are longer or shorter than 28
      days.

      Arm 1:

      You will receive azacitidine by vein over about 1 hour or as an injection under the skin. You
      will receive this drug either on Days 1-7 of each cycle, or on Days 1-5 and then 8 and 9 of
      each cycle. The study doctor will tell you how and when you will receive the drug, and may
      change the method or schedule if it is in your best interest.

      You will also receive nivolumab by vein over about 1 hour on Days 1 and 14 (+/- 3 days) of
      Cycles 1-4 and then on Day 1 only of Cycles 5 and beyond.

      Arm 2:

      You will receive azacitidine by vein over about 1 hour or as an injection under the skin. You
      will receive this drug either on Days 1-7 of each cycle, or on Days 1-5 and then 8 and 9 of
      each cycle. The study doctor will tell you how and when you will receive the drug, and may
      change the method or schedule if it is in your best interest.

      You will also receive nivolumab by vein over about 1 hour on Days 1 and 14 (+/- 3 days) of
      Cycles 1-4 and then on Day 1 only of Cycles 5 and beyond.

      You will receive ipilimumab by vein over 90 minutes starting on Day 1 and every 6 (or 12)
      weeks (+/-3 days) after that. You will receive a total of 4 doses of ipilimumab every 6 (or
      12) weeks and then stop therapy. If you have evidence of relapse or seem to be benefitting
      you may continue the ipilimumab every 6 (or 12) weeks.

      Depending on how the disease responds to the study drugs, the number of days you receive the
      study drugs may change. Your doctor will discuss this with you.

      If the study doctor thinks it is in your best interest, your dose of azacitidine and/or
      nivolumab may be changed and/or delayed.

      Study Visits:

      On Day 1 of each cycle (+/- 4 days):

        -  You will have a physical exam.

        -  You will have an EKG.

      One (1) time each week during Cycles 1-3 and then 1 time every 2-4 weeks after Cycle 3, blood
      (about 1 tablespoon) will be drawn for routine tests. If the doctor thinks it is needed, you
      may have this blood draw more often. If the doctor thinks it is acceptable, you may have
      these blood draws at a local lab or clinic. The results will be sent to the study doctor at
      MD Anderson.

      On Day 28 of Cycle 1 (+/- 7 days) and then every 1-3 cycles after that, you will have a bone
      marrow aspiration/biopsy to check the status of the disease.

      Any time that the doctor thinks it is needed while you are on study:

        -  Blood (about 1-2 tablespoons) may be drawn for routine tests.

        -  You may have a bone marrow aspiration/biopsy to check the status of the disease.

      Length of Study:

      You will receive nivolumab and azacitidine for as long as the doctor thinks it is in your
      best interest. You will no longer be able to take the study drugs if the disease gets worse,
      if intolerable side effects occur, or if you are unable to follow study directions.

      Your participation on the study will be over after the follow-up visits.

      End-of-Study Visit:

      Within 14 days after your last dose of study drugs:

        -  You will have a physical exam.

        -  Blood (about 2-3 tablespoons) will be drawn for routine tests.

        -  If the doctor thinks it is needed, you will have a bone marrow aspirate/biopsy to check
           the status of the disease.

      Follow-Up:

      You will be called about 30 days after your end-of-study visit and asked if you have had any
      side effects and/or started any new treatment(s). This call should last about 5 minutes. You
      may also be asked to come into the clinic for a physical exam, if the study staff thinks it
      is needed.

      Long-Term Follow-Up:

      If the disease appears to be getting better while you are taking the study drugs, you will be
      called every 3-6 months for up to 5 years. Each call should last about 5 minutes. You may
      also be asked to come into the clinic for a physical exam, if the study staff thinks it is
      needed.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">April 2015</start_date>
  <completion_date type="Anticipated">April 2020</completion_date>
  <primary_completion_date type="Anticipated">April 2019</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Maximum Tolerated Dose (MTD) of 5-azacytidine and Nivolumab</measure>
    <time_frame>28 days</time_frame>
    <description>The dose level at which 0-1/6 patients experience a dose limiting toxicity (DLT) in the first 28 days of treatment will be MTD. DLT defined as clinically significant non-hematologic adverse event or abnormal laboratory value assessed as unrelated to disease progression, intercurrent illness, or concomitant medications and occurring during the first cycle on study.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Overall Response Rate (ORR)</measure>
    <time_frame>3 months</time_frame>
    <description>Overall response rate (ORR), defined as CR (complete remission) + CRp (complete remission with incomplete platelet recovery) + CRi (complete remission with incomplete count recovery) + PR (partial response) + marrow clearance of blasts within 3 months of treatment initiation among adult patients with refractory/ relapsed AML.</description>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Anticipated">182</enrollment>
  <condition>Leukemia</condition>
  <arm_group>
    <arm_group_label>Azacitidine + Nivolumab</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Dose Escalation Phase: Participants receive Azacitidine by vein over about 1 hour or as an injection under the skin. Participants receive this drug either on Days 1-7 of each cycle, or on Days 1-5 and then 8 and 9 of each cycle.
Participants receive Nivolumab by vein over about 1 hour on Days 1 and 14 of Cycles 1-4 and then on Day 1 only of Cycles 5 and beyond.
Dose Expansion Phase: Participants receive the maximum tolerated dose of Azacitidine and Nivolumab from Dose Escalation Phase.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Azacitidine + Nivolumab + Ipilimumab</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Dose Escalation Phase: Participants receive Azacitidine by vein over about 1 hour or as an injection under the skin. Participants receive this drug either on Days 1-7 of each cycle, or on Days 1-5 and then 8 and 9 of each cycle.
Participants receive Nivolumab by vein over about 1 hour on Days 1 and 14 of Cycles 1-4 and then on Day 1 only of Cycles 5 and beyond.
Participants receive Ipilimumab by vein starting on Day 1 and every 6 (or 12) weeks after that. Participants receive a total of 4 doses of Ipilimumab every 6 (or 12) weeks and then stop therapy. If participant has evidence of relapse or seems to be benefitting, Ipilimumab may continue every 6 (or 12) weeks.
Dose Expansion Phase: Participants receive the maximum tolerated dose of Azacitidine and Nivolumab from Dose Escalation Phase.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Phase II Salvage Cohort</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Cohort consists of participants with relapsed/refractory AML.
Participants receive the maximum tolerated dose of Azacitidine and Nivolumab from Dose Escalation Phase.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Phase II Frontline Older Cohort</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Cohort consists of newly diagnosed older AML participants (age â‰¥ 65).
Participants receive the maximum tolerated dose of Azacitidine and Nivolumab from Dose Escalation Phase.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>5-azacytidine</intervention_name>
    <description>Dose Escalation Phase Starting Dose: 75 mg/m2 subcutaneously (SQ) or intravenously (IV) on Days 1 - 7 of every 28 day cycle.
Dose Expansion Phase Starting Dose: Maximum tolerated dose from Dose Escalation Phase.</description>
    <arm_group_label>Azacitidine + Nivolumab</arm_group_label>
    <arm_group_label>Azacitidine + Nivolumab + Ipilimumab</arm_group_label>
    <arm_group_label>Phase II Salvage Cohort</arm_group_label>
    <arm_group_label>Phase II Frontline Older Cohort</arm_group_label>
    <other_name>Azacitidine</other_name>
    <other_name>5-aza</other_name>
    <other_name>Vidaza</other_name>
    <other_name>5-AZC</other_name>
    <other_name>AZA-CR</other_name>
    <other_name>Ladakamycin</other_name>
    <other_name>NSC-102816</other_name>
    <other_name>Azacytidine</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Nivolumab</intervention_name>
    <description>Dose Escalation Phase Starting Dose: 3.0 mg/kg by vein on Day 1 and Day 14 of each 5-azacytidine cycle for the first 4 cycles or until complete response (CR) (whichever occurs earlier) followed by a maintenance regimen (one dose of nivolumab on day 1 of each cycle of 5-azacytidine).
Dose Expansion Phase Starting Dose: Maximum tolerated dose from Dose Escalation Phase.</description>
    <arm_group_label>Azacitidine + Nivolumab</arm_group_label>
    <arm_group_label>Azacitidine + Nivolumab + Ipilimumab</arm_group_label>
    <arm_group_label>Phase II Salvage Cohort</arm_group_label>
    <arm_group_label>Phase II Frontline Older Cohort</arm_group_label>
    <other_name>BMS-936558</other_name>
  </intervention>
  <intervention>
    <intervention_type>Behavioral</intervention_type>
    <intervention_name>Phone Call</intervention_name>
    <description>Participant called about 30 days after end-of-study visit. If disease appears to be getting better while taking study drugs, participant called every 3-6 months for up to 5 years.</description>
    <arm_group_label>Azacitidine + Nivolumab</arm_group_label>
    <arm_group_label>Azacitidine + Nivolumab + Ipilimumab</arm_group_label>
    <arm_group_label>Phase II Salvage Cohort</arm_group_label>
    <arm_group_label>Phase II Frontline Older Cohort</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ipilimumab</intervention_name>
    <description>Dose Escalation Phase Starting Dose: 1.0 mg/kg by vein every 12 weeks.
Dose Expansion Phase Starting Dose: Maximum tolerated dose from Dose Escalation Phase.</description>
    <arm_group_label>Azacitidine + Nivolumab + Ipilimumab</arm_group_label>
    <other_name>Yervoy</other_name>
    <other_name>BMS-734016</other_name>
    <other_name>MDX010</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Arm 1 Salvage cohort: Patients with AML or biphenotypic or bilineage leukemia who have
             failed prior therapy. Patients with AML should have failed prior therapy or have
             relapsed after prior therapy will be eligible for Arm 1. Arm 2 Salvage cohort:
             Patients with AML who have failed up to one prior therapy (i.e. salvage 1 or 2 status)
             will be eligible for Arm 2 relapse cohort. Allogeneic stem cell transplant for
             patients in remission at the time of stem cell transplant will not be considered a
             salvage regimen. Similarly, hydroxyurea if used alone will not be considered a salvage
             regimen. Arm 1 and 2 Frontline older cohort:. Patients age 65 years and above with
             previously untreated AML who are unfit for or decline standard induction therapy.

          2. (continued from Inclusion #1) Prior therapy with hydroxyurea, biological or targeted
             therapy (e.g. FLT3 inhibitors, other kinase inhibitors), or hematopoietic growth
             factors is allowed, however prior therapy with chemotherapy agents for the disease
             under study is not allowed. Patients may have received one dose of cytarabine (up to 2
             g/m2 administered at presentation for control) of hyperleucocytosis.

          3. Patients with MDS or CMML who received therapy for the MDS or CMML and progress to AML
             are eligible at the time of diagnosis of AML regardless any prior therapy for MDS or
             CMML. The WHO classification will be used for AML. Prior therapy for MDS or CMML will
             not be considered as a prior therapy for AML, hence such patients will be considered
             as frontline AML and eligible for the frontline elderly cohort.

          4. Prior therapy with hydroxyurea, chemotherapy, biological or targeted therapy (e.g.
             FLT3 inhibitors, other kinase inhibitors), or hematopoietic growth factors is allowed
             as long as within restrictions outlined in inclusion 4.2.1.

          5. Age &gt;/=18 years

          6. Eastern Cooperative Oncology Group (ECOG) Performance Status &lt;/=2

          7. Adequate organ function: total bilirubin &lt;/=2 times upper limit of normal (x ULN)
             (&lt;/=3 x ULN if considered to be due to leukemic involvement or Gilbert's syndrome);
             aspartate aminotransferase or alanine aminotransferase &lt;/=2.5 x ULN (&lt;/=5.0 x ULN if
             considered to be due to leukemic involvement); serum creatinine &lt;/=2 x ULN or GFR&gt;/=50

          8. Patients must provide written informed consent

          9. In the absence of rapidly progressing disease, the interval from prior treatment to
             time of initiation of 5-azacytidine and nivolumab will be at least 2 weeks OR at least
             5 half-lives for cytotoxic/noncytotoxic agents. The half-life for the therapy in
             question will be based on published pharmacokinetic literature (abstracts,
             manuscripts, investigator brochure's, or drug-administration manuals) and will be
             documented in the protocol eligibility document.Since the effect of both nivolumab and
             5-azacytidine may be delayed. Use of one dose of cytarabine (up to 2 g/m2) or
             hydroxyurea for patients with rapidly proliferative disease is allowed before the
             start of study therapy and during the study treatment. Concurrent therapy for CNS
             prophylaxis or continuation of therapy for controlled CNS disease is permitted

         10. Females must be surgically or biologically sterile or postmenopausal (amenorrheic for
             at least 12 months) or if of childbearing potential, must have a negative serum or
             urine pregnancy test within 72 hours before the start of the treatment

         11. Women of childbearing potential must agree to use an adequate method of contraception
             during the study and until 3 months after the last treatment. Males must be surgically
             or biologically sterile or agree to use an adequate method of contraception during the
             study until 3 months after the last treatment. Adequate methods of contraception
             include:total abstinence when this is in line with the preferred and usual lifestyle
             of the patient. Periodic abstinence

         12. (continued from Inclusion #10.) (e.g., calendar, ovulation, symptothermal,
             post-ovulation methods) and withdrawal are not acceptable methods of contraception.
             Female sterilization (have had surgical bilateral oophorectomy with or without
             hysterectomy) or tubal ligation at least six weeks before taking study treatment. In
             case of oophorectomy alone, only when the reproductive status of the woman has been
             confirmed by follow up hormone level assessment Male sterilization (at least 6 months
             prior to screening). For female patients on the study, the vasectomized male partner
             should be the sole partner for that patient. Combination of any of the two following
             (a+b or a+c or b+c).

         13. (continued). Use of oral, injected or implanted hormonal methods of contraception or
             other forms of hormonal contraception that have comparable efficacy (failure rate
             &lt;1%), for example hormone vaginal ring or transdermal hormone contraception b.
             Placement of an intrauterine device (IUD) or intrauterine system (IUS) c. Barrier
             methods of contraception: Condom or Occlusive cap (diaphragm or cervical/vault caps)
             with spermicidal foam/gel/film/cream/ vaginal suppository. In case of use of oral
             contraception, women should have been stable on the same pill before taking study
             treatment.Note: Oral contraceptives are allowed but should be used in conjunction with
             a barrier method of contraception due to unknown effect of drug-drug interaction.

         14. (continued). Women are considered post-menopausal and not of child bearing potential
             if they have had 12 months of natural (spontaneous) amenorrhea with an appropriate
             clinical profile (e.g. age appropriate, history of vasomotor symptoms) or have had
             surgical bilateral oophorectomy (with or without hysterectomy) or tubal ligation at
             least six weeks ago. In the case of oophorectomy alone, only when the reproductive
             status of the woman has been confirmed by follow up hormone level assessment is she
             considered not of child bearing potential.

         15. Patients with GVHD active &lt; grade 2 who are on a stable dose of immunosuppressive
             therapy (tacrolimus, cyclosporine, or other) for &gt; 2 weeks will be included. Note:
             Subjects may be using systemic corticosteroids or topical or inhaled corticosteroids.

        Exclusion Criteria:

          1. Patients with known allergy or hypersensitivity to nivolumab, ipilimumab,
             5-azacytidine, or any of their components.

          2. Patients with a known history of severe interstitial lung disease or severe
             pneumonitis or active pneumonitis that is uncontrolled in the opinion of the treating
             physician.

          3. Patients who have previously been treated with nivolumab and/or ipilimumab in
             combination with 5-azacytidine will be excluded.

          4. Patients with a known history of any of the following autoimmune diseases are
             excluded: (a) patients with a history of inflammatory bowel disease (including Crohn's
             disease and ulcerative colitis) (b) patients with a history of rheumatoid arthritis,
             systemic progressive sclerosis [scleroderma], Systemic Lupus Erythematosus, autoimmune
             vasculitis [e.g., Wegener's Granulomatosis]).

          5. Patients with organ allografts (such as renal transplant) are excluded

          6. Patients with active GVHD &gt; grade 2 will be excluded. Patients with recent increase in
             the immunosuppressive medication dose within last 2 weeks to control GVHD will not be
             included. Patients with grade 1 or lower GVHD on &lt;/= 10 mg prednisone without any
             additional immunosuppressive therapies (tacrolimus, prograf, etc) will be eligible.

          7. Patients with symptomatic CNS leukemia or patients with poorly controlled CNS
             leukemia.

          8. Active and uncontrolled disease/(active uncontrolled infection, uncontrolled
             hypertension despite adequate medical therapy, active and uncontrolled congestive
             heart failure NYHA class III/IV, clinically significant and uncontrolled arrhythmia)
             as judged by the treating physician.

          9. Patients with known Human Immunodeficiency Virus seropositivity will be excluded.

         10. Known to be positive for hepatitis B by surface antigen expression. Known to have
             active hepatitis C infection (positive by polymerase chain reaction or on antiviral
             therapy for hepatitis C within the last 6 months)

         11. Any other medical, psychological, or social condition that may interfere with study
             participation or compliance, or compromise patient safety in the opinion of the
             investigator

         12. Patients unwilling or unable to comply with the protocol.

         13. Pregnant or breastfeeding

         14. Acute promyelocytic leukemia (APL).
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Naval Daver, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>M.D. Anderson Cancer Center</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Naval Daver, MD</last_name>
    <phone>713-794-4392</phone>
  </overall_contact>
  <location>
    <facility>
      <name>University of Texas MD Anderson Cancer Center</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://www.mdanderson.org</url>
    <description>University of Texas MD Anderson Cancer Center Website</description>
  </link>
  <verification_date>March 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 19, 2015</study_first_submitted>
  <study_first_submitted_qc>March 24, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 25, 2015</study_first_posted>
  <last_update_submitted>March 19, 2018</last_update_submitted>
  <last_update_submitted_qc>March 19, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">March 21, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Leukemia</keyword>
  <keyword>Acute myeloid leukemia</keyword>
  <keyword>AML</keyword>
  <keyword>Refractory/ relapsed</keyword>
  <keyword>5-azacytidine</keyword>
  <keyword>Azacitidine</keyword>
  <keyword>5-aza</keyword>
  <keyword>Vidaza</keyword>
  <keyword>5-AZC</keyword>
  <keyword>AZA-CR</keyword>
  <keyword>Ladakamycin</keyword>
  <keyword>NSC-102816</keyword>
  <keyword>Azacytidine</keyword>
  <keyword>Nivolumab</keyword>
  <keyword>BMS-936558</keyword>
  <keyword>Phone calls</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Leukemia</mesh_term>
    <mesh_term>Leukemia, Myeloid</mesh_term>
    <mesh_term>Leukemia, Myeloid, Acute</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Nivolumab</mesh_term>
    <mesh_term>Azacitidine</mesh_term>
    <mesh_term>Antibodies, Monoclonal</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

